Enlivex Therapeutics Ltd
ENLV
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.69M
Close$
$0.03
96.7% downside
Current Fair Value
96.7% downsideOvervalued by 96.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.69 Million |
|---|---|
| Enterprise Value | $18.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $27.04 |
| Beta | 1.49 |
| Outstanding Shares | 45,445,272 |
Return
| Return on Equity | 63.85% |
|---|---|
| Return on Assets | 53.10% |
| Return on Invested Capital | -0.63% |
Valuation & Multiples
| P/E Ratio | 0.03 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.25 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 30, 2026
EPS Estimate
$-0.03
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 22, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 43.50% |
|---|---|
| Total Calls | 24,100▼ 2.03% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.01%▲ 2.51% |
|---|---|
| Total Invested | $3.38M▲ 263.73% |
| Investors Holding | 36▲ 9.00% |
ESG Score
No data
About Enlivex Therapeutics Ltd
CEO: Dror Mevorach